CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke

[1]  A. Algra,et al.  Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke , 1997, Journal of the Neurological Sciences.

[2]  R. Collins,et al.  Hospital management of acute ischemic stroke in China. , 1997, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[3]  Peter Sandercock,et al.  The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.

[4]  R. Collins,et al.  Aspirin versus clopidogrel: the wrong question? , 1997, The Lancet.

[5]  David Schultz,et al.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.

[6]  H. Diener,et al.  European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke 1 1 ESPS-2 Writing Committee , 1996, Journal of the Neurological Sciences.

[7]  S. Palter.  Ethics of Clinical Trials , 1996, Seminars in reproductive endocrinology.

[8]  Multicentre Acute Stroke Trial—Italy Group.  Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke , 1995, The Lancet.

[9]  L. Munari,et al.  RANDOMIZED CONTROLLED TRIAL OF STREPTOKINASE, ASPIRIN, AND COMBINATION OF BOTH IN TREATMENT OF ACUTE ISCHEMIC STROKE , 1995 .

[10]  P. Sandercock,et al.  Acute Stroke Treatment in UK Hospitals: The Stroke Association Survey of Consultant Opinion , 1995, Journal of the Royal College of Physicians of London.

[11]  J. Kent,et al.  Consultant views on the use of aspirin in acute cerebrovascular disease: implications for clinical trials. , 1994, Postgraduate medical journal.

[12]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[13]  M. Cullen.  Introducing New Treatment for Cancer. Practical, Ethical and Legal Problems , 1992, British Journal of Cancer.

[14]  K. Chen,et al.  Ischemic stroke treated with Ligusticum chuanxiong. , 1992, Chinese medical journal.

[15]  E. Feldmann,et al.  Chinese‐white differences in the distribution of occlusive cerebrovascular disease , 1990, Neurology.

[16]  E. Woo,et al.  Cerebrovascular disease in Hong Kong Chinese. , 1990, Stroke.

[17]  H. Adams,et al.  Use of antithrombotic drugs in the treatment of acute ischemic stroke , 1989, Neurology.

[18]  H. Schouten,et al.  Interobserver agreement for the assessment of handicap in stroke patients. , 1988, Stroke.

[19]  K. McPherson,et al.  Secondary prevention of vascular disease by prolonged antiplatelet treatment , 1988, British medical journal.

[20]  B. Schoenberg,et al.  Cerebrovascular disease in the People's Republic of China , 1985, Neurology.

[21]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[22]  P. Armitage,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.

[23]  THE WORLD HEALTH ORGANIZATION , 1954 .

[24]  C. Warlow,et al.  How Reliable Are Simple Questions in Assessing Outcome after Stroke , 1997 .

[25]  James Ahlquist.  Oxford Textbook of Medicine , 1997, Journal of the Royal College of Physicians of London.

[26]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[27]  A. Lowenthal.  The European Stroke Prevention Study , 1988, Acta neurologica Belgica.